History of Randomized Controlled Trials in the Treatment of Pediatric Nephrotic Syndrome and Precision Medicine
Glomerular Diseases · 05.09.2026 · 6 (1) · 354-362
DOI: 10.1159/gdz/acyag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glomerular Diseases, online erschienen am 27.10.2026. Verfasst von Ifeoma Anochie und 4 weiteren Autor:innen. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Society of Nephrology Renal Sisters Program, NIH/NIDDK.
Abstract (Originalsprache)
Background The diagnosis and treatment of nephrotic syndrome (NS) dates back to Hippocrates. The treatment has undergone a significant transition from the use of intramuscular injections of cortisone to the use of oral prednisolone and a group of other immunosuppressive medications. Nevertheless, despite intense investigations into the etiologies and targeted treatments, the full potential for precision medicine as it applies to pediatric glomerular diseases remains unfilled. A literature search was completed of all randomized clinical trials in pediatric NS. The International Study of Kidney Disease in Children (ISKDC) conducted the first international collaborative randomized blinded controlled trial in pediatric nephrology in the 1960s, which provided the framework to this day of all subsequent randomized controlled trials (RCT) of NS in children. Optimal therapy of patients with frequent relapsing steroid-sensitive NS and steroid-resistant primary focal segmental glomerulosclerosis (FSGS) has remained challenging with treatment failures, complications, and impairment in the quality of life of the patients. Summary The discovery of biomarkers associated with NS has led to the innovation of precision medicine in the management of glomerular disease, which is tailored to individual patients. This review tracked the life course trajectory of RCTs in the treatment of NS, including steroid-sensitive, steroid-resistant NS and FSGS, and advanced therapies to provide individualized therapies which are based on biomarkers from Neptune Match Clinical Trials, FONT, DUET, and APOL1 studies to improve treatment outcomes and minimize side effects of unnecessary immunosuppressants (precision medicine). Key Messages The treatment of NS in pediatric patients has advanced significantly from the early use of corticosteroids to the current promise of new targeted non-immunosuppressant therapies. A review of the major RCTs in the field, from the seminal ISKDC to the present, provides new insights into the mechanisms responsible for glomerular conditions, including FSGS, and the application of advances in targeted therapies using unique biomarkers to implement the potential of precision medicine in alleviating the burden of chronic glomerular kidney disease in children and adolescents.
Förderung
- International Society of Nephrology Renal Sisters Program
- NIH/NIDDK
Zitieren
APA
Anochie, I., Itoku, A., Mishra, A., Reidy, K. J., & Kaskel, F. J. (2026). History of Randomized Controlled Trials in the Treatment of Pediatric Nephrotic Syndrome and Precision Medicine. Glomerular Diseases, 6(1), 354-362. https://doi.org/10.1159/gdz/acyag001
Vancouver
Anochie I, Itoku A, Mishra A, Reidy KJ, Kaskel FJ. History of Randomized Controlled Trials in the Treatment of Pediatric Nephrotic Syndrome and Precision Medicine. Glomerular Diseases. 2026;6(1):354-362. doi:10.1159/gdz/acyag001
BibTeX
@article{Anochie2026,
author = {Anochie, Ifeoma and Itoku, Ai and Mishra, Aparajita and Reidy, Kimberly J and Kaskel, Frederick J},
title = {History of Randomized Controlled Trials in the Treatment of Pediatric Nephrotic Syndrome and Precision Medicine},
journal = {Glomerular Diseases},
year = {2026},
volume = {6},
number = {1},
pages = {354--362},
doi = {10.1159/gdz/acyag001}
}
EUVIMED